Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$102.58 USD

102.58
1,970,294

+1.92 (1.91%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $102.37 -0.21 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (202 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

New Strong Buy Stocks for March 1st

BMA, CAH, RCL, SPXC and RITM have been added to the Zacks Rank #1 (Strong Buy) List on March 1, 2023.

Best Income Stocks to Buy for March 1st

BMA, CAH and RITM made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 1, 2023.

Inari Medical (NARI) Q4 Earnings Improve Y/Y, Gross Margin Down

Inari Medical's (NARI) fourth-quarter earnings miss, while sales match estimates. Gross margin improves while the company incurs losses at the operating level.

Merit Medical (MMSI) Q4 Earnings Top Estimates, Gross Margin Up

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the fourth quarter.

Integra's (IART) Q4 Earnings Miss Estimates, Margins Down

Integra's (IART) Q4 revenues are impacted by the decline in the Tissue Technologies segment.

Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DENTSPLY SIRONA (XRAY) Q4 Earnings Beat Estimates, Sales Up Y/Y

DENTSPLY SIRONA's (XRAY) Q4 revenues improve year over year. Challenging macro headwinds linger.

National Vision (EYE) Q4 Earnings Top Estimates, Margins Fall

National Vision's (EYE) Q4 adjusted comparable store sales growth is driven by ongoing strength within America's Best and Eyeglass World sales.

Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw

Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.

Chemed (CHE) Q4 Earnings Surpass Estimates, Margins Expand

Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.

3 Reasons Why Growth Investors Shouldn't Overlook Cardinal (CAH)

Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Philips' (PHG) New Innovation to Boost Neurovascular Diagnosis

Philips (PHG) announces its latest Azurion neuro biplane system, which aims to improve the diagnosis of stroke and major neurovascular diseases. The system is designed for superior patient care.

Patterson Companies (PDCO) Misses on Q3 Earnings, Lowers EPS View

Patterson Companies' (PDCO) third-quarter fiscal 2024 results reflect an improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales appear weak.

Inogen (INGN) Q4 Earnings Miss Estimates, Gross Margin Improves

Inogen's (INGN) fourth-quarter earnings and revenues miss their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Masimo (MASI) Q4 Earnings Beat Estimates, Margins Decline

Despite strength in the Hearables category, Masimo's (MASI) overall fourth-quarter results reflect soft performances.

OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.

Insulet (PODD) Q4 Earnings, Revenues Top Mark, Margins Expand

In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.

Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down

Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.

Alcon (ALC) Q4 Earnings Beat Estimates, Margins Expand

Alcon (ALC) delivers impressive performance across its franchises in the fourth quarter of 2023.

Benjamin Rains headshot

How to Find Top-Ranked Stocks to Buy in March

Exploring how investors can use the Filtered Zacks Rank 5 Stock Screen to help find potentially winning stocks to buy in March and throughout what looks set to be a strong 2024.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.

Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity

Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.

GE HealthCare (GEHC), Biofourmis Partner to Boost At-Home Care

GE HealthCare (GEHC) collaborates with Biofourmis to facilitate the patient's journey throughout the healthcare system and make the transition from hospital to home care easier.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.